1 / 19

Call for action to prevent CV disease & diabetes in Asia: New strategies for intervention

New frontiers in Diabetes management. New frontiers in Diabetes management. Call for action to prevent CV disease & diabetes in Asia: New strategies for intervention. Key-slides prepared and presented at CDMC on April 20, 2013 in Hanoi, Vietnam by John Deanfield, MD

lynton
Download Presentation

Call for action to prevent CV disease & diabetes in Asia: New strategies for intervention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New frontiers in Diabetes management New frontiers in Diabetes management Call for action to prevent CV disease & diabetes in Asia: New strategies for intervention Key-slides prepared and presented at CDMC on April 20, 2013 in Hanoi, Vietnam by John Deanfield, MD University College London London, United Kingdom

  2. Death Rates from All Circulatory Disease in England 1993-2011 180 A fall of 55% since baseline 160 140 Target: 40% minimum reduction from 1995-97 120 100 Death / 100,000 population 80 60 40 Immortality Guaranteed by 2026 20 0 1993/5 1995/7 1997/9 2001/3 2003/5 2005/7 2007/9 2009/11 2009/11 1999/2001 Progress target B/L Source: ONS (ICD9 390-459; ICD10 I00-I99)

  3. Evolution of Atherosclerosis Genetic Environmental Clinical Events Age (yrs) 0 20 40 60

  4. Forecasting Future CVD in USA 900 800 700 600 500 Billions 2008 $ 400 300 200 Indirect Direct 100 0 2028 2026 2024 2016 2014 2015 2022 2029 2010 2018 2023 2025 2027 2012 2013 2017 2019 2020 2021 2030 2011 Heidenreich Circ 2011; 123: 933-944

  5. Coronary Heart Disease Mortality in Beijing 1984-1999 2500 1822 Extra deaths Attributable to Risk Factor Changes 2000 Cholesterol 77% 1000 Diabetes 19% BMI 4% Smoking 1% 500 0 642 fewer deaths by treatments AMI treatments 41% Hypertension treatment 24% Secondary prevetion 11% Heart failure 10% Aspirin for Angina 10% Angina: CABG & PTCA 2% -500 -1000 1999 1984 Critchley J. Circulation, 2004;110:1236-1244

  6. Potential Impact of Annual 0.5% RF Reduction on CHD Deaths in China: 1999-2010 Cheng BMC Public Health 2009, 9:30 1-10

  7. Potentially Modifiable Risk Factorsand MI : INTERHEART Study 15152 Cases 14820 Controls in 262 Centres in 52 Countries 9 RFs acounted for 90% of MI in men and 94% in women 3 Odds Ratio 2 1 0 BP DM Stress Fr/Veg Obesity Alcohol Smoking Phys Act. 60 ApoB/ApoA1 40 PAR (%) 20 0 -20 Yusuf Lancet September 11 2004

  8. Diabetes in China : 1994-2008 Yang NEJM 2010 362 1090-101

  9. BMI and Diabetes Prevalence: DECODA Study Ma Ann. N.Y. Acad. Sci. 1281 (2013) 64–91

  10. Diabetes in Asia: Age 20-79yrs Diabetes Death from Diabetes Chan JAMA 2009; 301: 2129-2140

  11. Diabetes in Asia: Age 20-79yrs Diabetes Death from Diabetes • Obesity • Beta cell function • Visceral fat • Developmental factors • Diet • Genetic susceptability • Smoking • Other factors eg. Thalassaemia Chan JAMA 2009; 301: 2129-2140

  12. Mortality from NCDs in Asian Women Rajadurai, J. et al. Nat. Rev. Cardiol. 9, 464–477 (2012)

  13. Incremental Benefit of Intensive Lowering of LDL and Blood Pressure 0.8 P<0.001 for trend 0.6 0.4 Change PercentAtheroma Volume 0.2 0.0 LDL <70 SBP <120 LDL <70 SBP >120 LDL >70 SBP <120 LDL >70 SBP >120 Chhatriwalla, Nicholls J AmerCollCardiol 2009

  14. BMI and Hypertension: Johns Hopkins Precursor Study 508 of 1337 subjects developed hypertension over 46 years ShihabCirculation. 2012; 126: 2983-2989

  15. Cost effectiveness of interventions for CVD, DM, and tobacco use OrtegónBMJ 2012; 344

  16. Impact of Metabolic Syndrome in Youth on cIMT MagnussenJ Am Coll Cardiol 2012; 60: 1631–9

  17. Potential Benefit of CV RF treatment in Obesity Excess Deaths from CHD Excess Total CHD Events 100000 100000 Average projection Treatment for DBP and LDL Treatment for DBP, LDL and HDL 10000 10000 1000 1000 No. of excess events No. of excess events 100 100 10 10 Average projection Treatment for DBP and LDL Treatment for DBP, LDL and HDL 1 1 2021 2023 2025 2027 2029 2031 2033 2035 2021 2023 2025 2027 2029 2031 2033 2035 Year Year Bibbins-Domingo NEJM 2007; 357: 2371-2379

  18. CV disease is preventable “Life-long Rx likely to be cost-effective and often cost saving” Circulation 2011;124:967-990

  19. CV Risk Management Strategies • Lifetime approach to CV management is key to tackling the increasing population risk • Emerging obesity and resulting diabetes is a particular issue for Asia • Developing countries need to increase national capacity, effective treatments and improve primary prevention

More Related